---
title: Omics-based biomarkers discovery for Alzheimer's disease
date: '2022-11-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/36348101/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Zkrxt7ktlCbHBXEV3v65xxSnkSWNsJ1A6Fq3gBniKhGfIUslK&fc=20210907212339&ff=20221110202641&v=2.17.8
source: metablomics[MeSH Terms]
description: Alzheimer's disease (AD) is the most common neurodegenerative disorders
  presenting with the pathological hallmarks of amyloid plaques and tau tangles. Over
  the past few years, great efforts have been made to explore reliable biomarkers
  of AD. High-throughput omics are a technology driven by multiple levels of unbiased
  data to detect the complex etiology of AD, and it provides us with new opportunities
  to better understand the pathophysiology of AD and thereby identify potential ...
---
Alzheimer's disease (AD) is the most common neurodegenerative disorders presenting with the pathological hallmarks of amyloid plaques and tau tangles. Over the past few years, great efforts have been made to explore reliable biomarkers of AD. High-throughput omics are a technology driven by multiple levels of unbiased data to detect the complex etiology of AD, and it provides us with new opportunities to better understand the pathophysiology of AD and thereby identify potential ...